Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Non-Current Liabilities: 2017-2024

Historic Total Non-Current Liabilities for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2024 value amounting to $124.2 million.

  • Seres Therapeutics' Total Non-Current Liabilities fell 36.12% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.8 million, marking a year-over-year decrease of 36.12%. This contributed to the annual value of $124.2 million for FY2024, which is 69.09% down from last year.
  • Latest data reveals that Seres Therapeutics reported Total Non-Current Liabilities of $124.2 million as of FY2024, which was down 69.09% from $401.8 million recorded in FY2023.
  • Seres Therapeutics' 5-year Total Non-Current Liabilities high stood at $401.8 million for FY2023, and its period low was $124.2 million during FY2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $336.6 million (2022), whereas its average is $287.5 million.
  • As far as peak fluctuations go, Seres Therapeutics' Total Non-Current Liabilities surged by 58.86% in 2022, and later tumbled by 69.09% in 2024.
  • Over the past 5 years, Seres Therapeutics' Total Non-Current Liabilities (Yearly) stood at $167.2 million in 2020, then climbed by 26.72% to $211.9 million in 2021, then surged by 58.86% to $336.6 million in 2022, then rose by 19.39% to $401.8 million in 2023, then slumped by 69.09% to $124.2 million in 2024.